36340-89-3

Upstream product

• 853181-28-9 methyl 4-(4-fluorophenyl)-2-isopropyl-1,4,4a,5,6,7-hexahydro-[1,8]naphthyridine-3-carboxylate 
• 124-63-0 methanesulfonyl chloride 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 4518-10-9 Methyl 3-aminobenzoate 
• 108-77-0 1,3,5-trichloro-2,4,6-triazine 
• 1877-77-6 3-aminobenzenemethanol 

Downstream Products

• 118-58-1 benzyl salicylate 
• 1346652-39-8 (3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)methanol 
• 1346652-38-7 methyl 3-(4-(6-(tert-butoxycarbonylamino)hexylamino)-6-chloro-1,3,5-triazin-2-ylamino)benzoate 

Relevant academic research and scientific papers

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infect

HMG-COA REDUCTASE INHIBITORS AND METHOD

Compounds are provided having the following structure (I) and pharmaceutically acceptable salts thereof, A is (II) or (III); wherein R1, R2, R3, R4, U, V, W, Y, and n are as defined above, which compounds are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis and may be employed as hormone replacement therapy. A method for treating the above diseases employing the above compounds is also provided.